Driven by improved domestic pharmaceutical innovation and accelerated global expansion, Chinese pharmaceutical companies have rising demands for professional services including licensing, outbound BD, investment & financing, patent protection and pharmaceutical compliance, standing at a critical turning point from domestic innovation to global value realization.Meanwhile, amid evolving 2026 life sciences financing landscape, international regulatory policies and cross-border transaction practices, pharmaceutical enterprises encounter increasingly complicated legal and compliance challenges in overseas IPO, License Out, NewCo cooperation, cross-border M&A and global operation.

Against such backdrop, Fangda’s Life Sciences practice groups co-organize this special session together with TONACEA. Focused on core legal and commercial issues concerning Chinese pharma globalization, the discussion covers three topics: Investment & Capital Market, Practical Matters of Outbound Pipeline Deals and Cutting-edge Compliance Highlights, involving globalization route selection, cross-border risk control, key clause design for License Out, MNC’s acquisition of China-based assets, IP, cross-border data, human genetic resources (HGR) compliance, antitrust, sanctions & export controls and cross-border tax optimization. Combined with latest cases and market trends, the session delivers practical suggestions and forward-looking insights to help Chinese innovative medicines achieve high-quality global value monetization.

Meeting time: Wednesday, July 22, 2026, from 14:00 to 17:00 (sign-in from 13:30 to 14:00)

14:00-14:15  Opening Remarks

14:15-15:00  Roundtable Discussion:Investment & Capital Market amid Chinese Pharma’s Global Expansion
（1）2026 Observations on Life Sciences Investment and Financing Landscape
（2）Overseas Expansion & Listing Options: Latest Regulatory Updates on Hong Kong Listings, US IPOs, Spin-off Listings and Red-chip Structures
（3）Key Legal Issues in Cross-border Transactions: Risk Control from Term Sheet to Closing

15:00-15:45   Roundtable Discussion:Core Legal Framework & Practical Highlights of Outbound Pipeline Transactions
（1）2026 Transaction Overview: Structuring & Driving Logic of License Out, NewCo, Co-Co, Platform Cooperation and Asset Acquisition
（3）Key Negotiation Points for License Out: Scope of Rights, Milestone Structuring, Diligent Obligations and Termination Provisions
（3）MNCs’ Acquisition of China-Based Assets: Deal Structure, Regulatory Barriers and Practical Solutions
（4）Patent Protection & Dispute Resolution: IP Risks and Dispute Prevention Mechanisms in Outbound Transactions (Overview)
 

15:45-16:00   Break

16:00-17:00  Roundtable Discussion:Frontier Compliance Topics for Chinese Pharma’s Global Expansion
（1）Cross-border Data & Human Genetic Resources (HGR) Compliance: Hidden Barriers for Outbound Transactions
（2）Latest Developments in Antitrust and Foreign Investment Screening
（3）Sanctions & Technology Export Controls: Two-Way Compliance Pressures for Outbound Chinese Pharma
（4）Tax Optimization and Structuring under Cross-border Frameworks

17:30  Cocktail Reception